Published in J Clin Oncol on April 20, 2008
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res (2010) 4.50
Translating insights from the cancer genome into clinical practice. Nature (2008) 4.37
Genomic Classification of Cutaneous Melanoma. Cell (2015) 3.91
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov (2009) 3.64
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
Clinical implications of the cancer genome. J Clin Oncol (2010) 3.11
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med (2011) 2.86
Melanoma: from mutations to medicine. Genes Dev (2012) 2.59
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One (2012) 2.21
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol (2012) 1.64
Melanoma: new insights and new therapies. J Invest Dermatol (2012) 1.54
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther (2009) 1.53
Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J Mol Diagn (2011) 1.53
Integrating BRAF/MEK inhibitors into combination therapy for melanoma. Br J Cancer (2009) 1.48
Mutation-driven drug development in melanoma. Curr Opin Oncol (2010) 1.43
Perspectives on the development of imatinib and the future of cancer research. Nat Med (2009) 1.42
A phase 2 trial of dasatinib in advanced melanoma. Cancer (2010) 1.40
Phosphoproteomic screen identifies potential therapeutic targets in melanoma. Mol Cancer Res (2011) 1.38
Analysis of the genome to personalize therapy for melanoma. Oncogene (2010) 1.33
Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer (2010) 1.24
Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol (2009) 1.21
Mucosal melanomas: a case-based review of the literature. Oncologist (2010) 1.20
A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS One (2010) 1.17
Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br J Cancer (2008) 1.17
Biomarkers in melanoma. Ann Oncol (2009) 1.17
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
A melanoma molecular disease model. PLoS One (2011) 1.15
Melanocytes in development and cancer. J Cell Physiol (2010) 1.15
High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. Cancer (2011) 1.13
Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol (2010) 1.13
Small molecules and targeted therapies in distant metastatic disease. Ann Oncol (2009) 1.08
Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer Discov (2011) 1.07
Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res (2010) 1.07
New strategies in melanoma: molecular testing in advanced disease. Clin Cancer Res (2012) 1.01
Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs (2011) 1.00
Targeting the RAS pathway in melanoma. Trends Mol Med (2011) 0.98
Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am (2011) 0.98
Genetics and genomics of melanoma. Expert Rev Dermatol (2009) 0.98
Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study. BMC Cancer (2010) 0.97
KIT as a therapeutic target in melanoma. J Invest Dermatol (2010) 0.97
Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas. World J Clin Oncol (2012) 0.94
A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma. Oncogene (2010) 0.92
Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment. Immunotherapy (2011) 0.91
Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma. Dermatol Res Pract (2011) 0.91
Pharmacogenomics of chemotherapeutic susceptibility and toxicity. Genome Med (2012) 0.89
Copy number gains in 11q13 and 8q24 [corrected] are highly linked to prognosis in cutaneous malignant melanoma. J Mol Diagn (2011) 0.89
Targeted therapy for melanoma: a primer. Surg Oncol Clin N Am (2011) 0.89
Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol (2013) 0.89
Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Lett (2015) 0.88
Melanoma biology and the promise of zebrafish. Zebrafish (2008) 0.88
Recent advances on skin-resident stem/progenitor cell functions in skin regeneration, aging and cancers and novel anti-aging and cancer therapies. J Cell Mol Med (2009) 0.88
Molecular targeted therapies in metastatic melanoma. Pharmgenomics Pers Med (2013) 0.87
Smad7 restricts melanoma invasion by restoring N-cadherin expression and establishing heterotypic cell-cell interactions in vivo. Pigment Cell Melanoma Res (2010) 0.87
Malignant melanoma arising in mature cystic teratoma of the ovary. Gynecol Oncol Case Rep (2011) 0.87
Applications of genomics in melanoma oncogene discovery. Hematol Oncol Clin North Am (2009) 0.87
Optimal management of metastatic melanoma: current strategies and future directions. Am J Clin Dermatol (2013) 0.86
The current state of targeted therapy in melanoma: this time it's personal. Semin Oncol (2012) 0.86
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res (2015) 0.85
Targeted therapy in melanoma - the role of BRAF, RAS and KIT mutations. EJC Suppl (2013) 0.85
Melanoma: from melanocyte to genetic alterations and clinical options. Scientifica (Cairo) (2013) 0.85
Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells. Arch Pathol Lab Med (2010) 0.84
Structural reengineering of imatinib to decrease cardiac risk in cancer therapy. J Clin Invest (2007) 0.84
Molecular profiling of melanoma and the evolution of patient-specific therapy. Semin Oncol (2011) 0.84
Narrowing the knowledge gaps for melanoma. Ups J Med Sci (2012) 0.84
Merkel cell carcinoma: correlation of KIT expression with survival and evaluation of KIT gene mutational status. Hum Pathol (2010) 0.84
Molecular testing in melanoma. Cancer J (2012) 0.83
A brief history of melanoma: from mummies to mutations. Melanoma Res (2012) 0.83
Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract. J Am Acad Dermatol (2014) 0.81
Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo. Oncotarget (2016) 0.81
Molecular bases of cutaneous and uveal melanomas. Patholog Res Int (2011) 0.81
The GIST of targeted therapy for malignant melanoma. Ann Surg Oncol (2014) 0.80
Molecular targets in melanoma: time for 'ethnic personalization'. Expert Rev Anticancer Ther (2012) 0.80
A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes. Immunotherapy (2012) 0.80
Simple, Sensitive and Accurate Multiplex Detection of Clinically Important Melanoma DNA Mutations in Circulating Tumour DNA with SERS Nanotags. Theranostics (2016) 0.79
Targeting melanoma by small molecules: challenges ahead. Pigment Cell Melanoma Res (2013) 0.79
BRAF and beyond: Tailoring strategies for the individual melanoma patient. J Carcinog (2014) 0.79
New treatment approaches in melanoma: current research and clinical prospects. Ther Adv Med Oncol (2013) 0.78
Melanoma: oncogenic drivers and the immune system. Ann Transl Med (2015) 0.78
Therapeutic opportunities in noncutaneous melanoma. Ther Adv Med Oncol (2009) 0.78
Systemic therapy of non-resectable metastatic melanoma. Cancers (Basel) (2010) 0.78
BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol (2012) 0.78
MicroRNAs as molecular classifiers for cancer. Cell Cycle (2011) 0.78
KGF Promotes Paracrine Activation of the SCF/c-KIT Axis from Human Keratinocytes to Melanoma Cells. Transl Oncol (2010) 0.78
Drug targets and predictive biomarkers in the management of metastatic melanoma. Pharmgenomics Pers Med (2012) 0.77
Oncogenic KIT mutations in different exons lead to specific changes in melanocyte phospho-proteome. J Proteomics (2016) 0.77
Esophageal melanomas harbor frequent NRAS mutations unlike melanomas of other mucosal sites. Virchows Arch (2009) 0.77
KIT in melanoma: many shades of gray. J Invest Dermatol (2015) 0.77
SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma. Ann Surg Oncol (2013) 0.76
Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies. Br J Cancer (2016) 0.76
Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation. Oncotarget (2015) 0.76
The evolution in melanoma treatment as a reflection of precision-oriented medicine. Oncol Lett (2012) 0.76
State of melanoma: an historic overview of a field in transition. Hematol Oncol Clin North Am (2014) 0.76
New horizons in melanoma treatment: targeting molecular pathways. Ochsner J (2010) 0.76
Evolving pharmacotherapies for the treatment of metastatic melanoma. Clin Med Insights Oncol (2013) 0.75
A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib. J Invest Dermatol (2013) 0.75
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (2006) 12.98
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 11.33
PDGFRA activating mutations in gastrointestinal stromal tumors. Science (2003) 11.11
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 8.69
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (2012) 8.00
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet (2007) 6.76
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol (2008) 6.43
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol (2008) 6.11
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol (2006) 6.00
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res (2005) 5.98
Biology of gastrointestinal stromal tumors. J Clin Oncol (2004) 5.89
Chromatin structure analyses identify miRNA promoters. Genes Dev (2008) 5.40
High-throughput mapping of the chromatin structure of human promoters. Nat Biotechnol (2007) 5.24
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood (2003) 5.07
Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell (2007) 4.75
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol (2010) 4.69
MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med (2006) 4.60
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med (2006) 4.52
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28
Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev (2006) 4.24
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol (2008) 4.10
Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol (2002) 4.09
Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol (2010) 4.01
The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol (2004) 3.84
PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol (2005) 3.73
Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell (2002) 3.72
BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol (2005) 3.68
Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell (2013) 3.63
Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer (2011) 3.55
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol (2009) 3.53
Melanocyte biology and skin pigmentation. Nature (2007) 3.43
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol (2007) 3.38
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood (2008) 3.30
Gastrointestinal stromal tumour. Lancet (2007) 3.25
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell (2007) 3.23
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
Gastrointestinal stromal tumour. Lancet (2013) 3.19
Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche. Science (2004) 3.12
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2008) 3.08
A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature (2011) 2.96
Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma. Cancer (2014) 2.94
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol (2009) 2.88
Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol (2002) 2.85
Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol (2002) 2.85
Determination of stromal signatures in breast carcinoma. PLoS Biol (2005) 2.84
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A (2009) 2.84
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol (2006) 2.81
Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol (2010) 2.80
Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell (2004) 2.80
GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature (2009) 2.77
"Pediatric-type" gastrointestinal stromal tumors in adults: distinctive histology predicts genotype and clinical behavior. Am J Surg Pathol (2011) 2.72
Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell (2006) 2.69
Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A (2010) 2.68
A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol (2008) 2.68
Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol (2006) 2.66
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res (2006) 2.61
Melanoma: from mutations to medicine. Genes Dev (2012) 2.59
KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res (2008) 2.57
KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol (2004) 2.51
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2005) 2.47
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol (2011) 2.46
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev (2006) 2.46
Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol (2013) 2.42
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest (2004) 2.40
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol (2011) 2.38